Allogene Therapeutics Inc [ALLO] stock prices are saw in change for the day to $1.03 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ALLO shares have lost -8.04% over the last week, with a monthly amount drifted -20.16%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Allogene Therapeutics Inc [NASDAQ: ALLO] stock has seen the most recent analyst activity on May 14, 2025, when Citizens JMP downgraded its rating to a Mkt Perform. Previously, Citizens JMP upgraded its rating to Mkt Outperform on March 14, 2025, and kept the price target unchanged to $5. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $11 on May 31, 2024. JMP Securities downgraded its rating to a Mkt Perform. Guggenheim downgraded its rating to Neutral for this stock on January 05, 2024. In a note dated December 08, 2023, Citigroup initiated an Buy rating and provided a target price of $7 on this stock.
The stock price of Allogene Therapeutics Inc [ALLO] has been fluctuating between $0.86 and $3.78 over the past year. Currently, Wall Street analysts expect the stock to reach $29 within the next 12 months. Allogene Therapeutics Inc [NASDAQ: ALLO] shares were valued at $1.03 at the most recent close of the market. An investor can expect a potential return of 2715.53% based on the average ALLO price forecast.
Analyzing the ALLO fundamentals
The Allogene Therapeutics Inc [NASDAQ:ALLO] reported sales of 0.00M for trailing twelve months, representing a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 146.95% with Operating Profit Margin at 12222.09%, Pretax Profit Margin comes in at 11449.09%, and Net Profit Margin reading is 11469.23%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.56 and Total Capital is -0.56. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0037 points at the first support level, and at 0.9774 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0626, and for the 2nd resistance point, it is at 1.0952.
Ratios To Look Out For
It’s worth pointing out that Allogene Therapeutics Inc [NASDAQ:ALLO]’s Current Ratio is 9.71. Also, the Quick Ratio is 9.71, while the Cash Ratio stands at 1.41.
Transactions by insiders
Recent insider trading involved MESSEMER DEBORAH M., Director, that happened on Jun 10 ’25 when 36885.0 shares were sold. Director, MESSEMER DEBORAH M. completed a deal on Jun 10 ’25 to buy 36885.0 shares. Meanwhile, SVP, Finance Yoshiyama Annie sold 9601.0 shares on Apr 21 ’25.
